Andrew J. Wilson, PhD

Dr. Wilson was recruited to Department of Obstetrics and Gynecology to identify novel epigenetic treatment strategies for ovarian cancer and was promoted to a Faculty position in 2011. He has continued to study new ways to sensitize chemoresistant, high-grade serous ovarian tumors to established DNA damaging chemotherapeutic agents, such as PARP inhibitors, with epigenetic drugs. He was recently funded to study a novel role for the orphan nuclear receptor NR4A1 as a therapeutic target to enhance PARP inhibitor response in ovarian cancer. He is also focused on improving the effectiveness and reducing toxicities of immune therapies in syngeneic mouse models of ovarian cancer, particularly targeting tumor-associated macrophages. Dr. Wilson is a member of the transdisciplinary Vanderbilt Ovarian Cancer Alliance (VOCAL), which promotes collaboration between investigators from diverse research backgrounds to increase translational research opportunities towards improving detection and treatment of ovarian cancer, and to raise community awareness of this devastating disease.